These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 2959049)

  • 21. A major role of ADP in thromboxane transfer experiments: studies in patients with platelet secretion defects.
    Rao AK; Willis J; Holmsen H
    J Lab Clin Med; 1984 Jul; 104(1):116-26. PubMed ID: 6429260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deficiency of (33P)2MeS-ADP binding sites on platelets with secretion defect, normal granule stores and normal thromboxane A2 production. Evidence that ADP potentiates platelet secretion independently of the formation of large platelet aggregates and thromboxane A2 production.
    Cattaneo M; Lombardi R; Zighetti ML; Gachet C; Ohlmann P; Cazenave JP; Mannucci PM
    Thromb Haemost; 1997 May; 77(5):986-90. PubMed ID: 9184415
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Platelets and cerebral ischemia].
    Leira R
    Neurologia; 1991 Feb; 6(2):39-40. PubMed ID: 1863461
    [No Abstract]   [Full Text] [Related]  

  • 24. Platelet-activating factor in septic shock.
    Koltai M; Hosford D; Braquet PG
    New Horiz; 1993 Feb; 1(1):87-95. PubMed ID: 7922397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mouse antithrombotic assay: the effects of Ca++ channel blockers are platelet-independent.
    Molinari A; Guarneri L; Pacei E; de Marchi F; Cerletti C; de Gaetano G
    J Pharmacol Exp Ther; 1987 Feb; 240(2):623-7. PubMed ID: 3806414
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effects of SIN-1, a metabolite of molsidomine, on paf-acether-blood platelets interactions].
    Nunez D; Russo-Marie F; Benveniste J
    Pathol Biol (Paris); 1987 Feb; 35(2 Pt 2):215. PubMed ID: 3550639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiplatelet activity of carnosol is mediated by the inhibition of TXA2 receptor and cytosolic calcium mobilization.
    Lee JJ; Jin YR; Lim Y; Hong JT; Kim TJ; Chung JH; Yun YP
    Vascul Pharmacol; 2006 Sep; 45(3):148-53. PubMed ID: 16916624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of MK-447 on platelet shape change, aggregation, and ATP release by collagen, ADP, and stable analogue of thromboxane A2 in rabbit platelets.
    Li BY; Zhou H; Qiao GF; Wang L; Li WH
    Zhongguo Yao Li Xue Bao; 1999 Jul; 20(7):627-30. PubMed ID: 10678127
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.
    Imanishi N; Murakami-Uchida M; Koike H; Natsume Y; Morooka S
    Arzneimittelforschung; 1994 Mar; 44(3):317-22. PubMed ID: 8192697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A role for platelet activating factor and platelets in the induction of bronchial hyperreactivity.
    Page CP
    Int J Tissue React; 1987; 9(1):27-32. PubMed ID: 3298115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Platelet-induced pulmonary hypertension and edema. A mechanism involving acetyl glyceryl ether phosphorylcholine and thromboxane A2.
    Heffner JE; Shoemaker SA; Canham EM; Patel M; McMurtry IF; Morris HG; Repine JE
    Chest; 1983 May; 83(5 Suppl):78S-79S. PubMed ID: 6839854
    [No Abstract]   [Full Text] [Related]  

  • 32. Thromboxane receptor antagonists and endotoxaemia.
    Mikhailidis DP; Whitworth NH; Barradas MA; Jeremy JY; Dandona P
    Eicosanoids; 1989; 2(1):59, 61-2. PubMed ID: 2633797
    [No Abstract]   [Full Text] [Related]  

  • 33. Platelets and thromboxane A2 in the pathogenesis of aging penile vascular changes and impotence.
    Bornman MS; Dormehl IC; Franz RC; Du Plessis DJ; Jacobs DJ
    Arch Androl; 1986; 17(3):233-4. PubMed ID: 3606277
    [No Abstract]   [Full Text] [Related]  

  • 34. The role of thromboxane A2 in experimental and human models of chronic glomerular damage.
    Patrono C; Pierucci A; Salvati P
    Adv Prostaglandin Thromboxane Leukot Res; 1989; 19():199-202. PubMed ID: 2526467
    [No Abstract]   [Full Text] [Related]  

  • 35. Bioassay of platelet-activating factor by release of [3H]serotonin.
    Henson PM
    Methods Enzymol; 1990; 187():130-4. PubMed ID: 2233338
    [No Abstract]   [Full Text] [Related]  

  • 36. [Thrombocyte activation factor: biochemical and pathophysiologic aspects].
    Svetlov SI; Serebrianyĭ VL
    Patol Fiziol Eksp Ter; 1989; (1):70-5. PubMed ID: 2497431
    [No Abstract]   [Full Text] [Related]  

  • 37. Thromboxane A2 and platelets as mediators of coronary arterial vasoconstriction in myocardial ischaemia.
    Schrör K
    Eur Heart J; 1990 Apr; 11 Suppl B():27-34. PubMed ID: 2194808
    [No Abstract]   [Full Text] [Related]  

  • 38. Eicosanoids and sudden cardiac death.
    Nowak J; Murray JJ; FitzGerald GA; Wehr CJ; Hammon JW; Oates JA
    Adv Prostaglandin Thromboxane Leukot Res; 1987; 17A():20-4. PubMed ID: 2959048
    [No Abstract]   [Full Text] [Related]  

  • 39. Proceedings of an International Symposium on Mechanisms of Platelet Activation and Control. London, United Kingdom, April 13-14, 1992.
    Adv Exp Med Biol; 1993; 344():1-272. PubMed ID: 7911646
    [No Abstract]   [Full Text] [Related]  

  • 40. Potential role of platelet-activating factor in renal pathophysiology.
    Camussi G
    Kidney Int; 1986 Feb; 29(2):469-77. PubMed ID: 3517457
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.